HEPA - Hepion Pharma's lead drug can 'potentially' lower the risk of ischemic stroke study shows

Hepion Pharmaceuticals (HEPA) has announced results from a translational research study in which its lead drug candidate, CRV431 decreased formation of a class of blood platelets, called ‘procoagulant platelets, and high levels of such platelets are associated with transient ischemic attack and stroke.Analysis showed decreased membrane exposure of phosphatidylserine, a marker of procoagulant platelets by up to 49%, and mean reduction of 29% vs. placebo. Also the study showed that CRV431 had no significant effect on platelet aggregation.CRV431 is a cyclophilin inhibitor derived from cyclosporin A, an immunosuppressant drug used in organ transplantation to prevent rejection.

For further details see:

Hepion Pharma's lead drug can 'potentially' lower the risk of ischemic stroke, study shows